Current therapies for ANCA-associated vasculitis

Area of Science:

• Immunology
• Rheumatology
• Internal Medicine

Background:

• ANCA-associated vasculitides (AAV) encompass granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).
• These are multisystem autoimmune diseases defined by necrotizing small- to medium-vessel vasculitis and anti-neutrophil cytoplasmic antibodies (ANCA).

Purpose of the Study:

• To review current therapeutic strategies for AAV, including induction and maintenance of remission.
• To identify key treatment goals, such as reducing toxicity and preventing relapse.
• To highlight future research directions in AAV management.

Main Methods:

• Literature review of current therapeutic strategies for ANCA-associated vasculitides.
• Analysis of treatment goals and emerging insights into disease pathogenesis.
• Identification of future research priorities.

Main Results:

• Current treatments involve glucocorticoids combined with conventional or biologic agents for remission induction and maintenance.
• Primary treatment goals include minimizing therapy toxicity, preventing disease relapse, and reducing long-term damage and morbidity.
• Emerging insights into AAV pathogenesis are guiding future research.

Conclusions:

• Optimizing maintenance therapy duration and frequency is crucial.
• Development of targeted therapeutic agents, informed by pathogenesis research, is a key future direction.
• Reducing treatment-related morbidity and disease-related damage remains paramount in AAV management.